Tag: PermaLink
ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression
The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor regression in preclinical models of...
Femtogenix Signs License Agreement with Iksuda Therapeutics
Iksuda Therapeutics, formerly known as Glythera, confirmed that it has signed a licensing agreement with Femtogenix. The agreement gives Iksuda access to Femtogenix’s therapeutic,...
Glythera and Cancer Research UK Collaborate in the Development of “Next-Gen”...
Cancer Research UK and Glythera, a company developing the "next-gen" antibody-drug conjugates or ADCs have agreed that Glythera receives exclusive, worldwide rights, to the...
Glythera Wins Grant to Develops Portfolio of PermaLink®-based ADCs
Glythera, a UK-based company has won a UK £ 1 million (US $ 1,12 million) Innovate UK grant to fund a new project to...
Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs
Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...
